Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
Authors
Keywords
anti-CD38 monoclonal antibody, Isatuximab, Multiple myeloma, Prior lines, Relapsed, Refractory
Journal
LEUKEMIA RESEARCH
Volume 104, Issue -, Pages 106576
Publisher
Elsevier BV
Online
2021-03-30
DOI
10.1016/j.leukres.2021.106576
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
- (2020) Saad Z Usmani et al. Lancet Haematology
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
- (2019) Paul G Richardson et al. LANCET ONCOLOGY
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)
- (2018) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
- (2018) Paul G Richardson et al. Future Oncology
- Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016
- (2018) Marc S. Raab et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
- (2018) Paul G. Richardson et al. Blood Cancer Journal
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Multiple Myeloma: Diagnosis and Treatment
- (2016) S. Vincent Rajkumar et al. MAYO CLINIC PROCEEDINGS
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapies targeting CD38 in Multiple Myeloma
- (2016) Djordje Atanackovic et al. OncoImmunology
- Guidelines for determination of the number of prior lines of therapy in multiple myeloma
- (2015) S. V. Rajkumar et al. BLOOD
- Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
- (2015) J Laubach et al. LEUKEMIA
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
- (2014) J. Deckert et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started